Aug 14, 2025 04:05PM
Jul 7, 2025 08:32AM
Jul 7, 2025 08:30AM
May 15, 2025 04:05PM
Mar 31, 2025 04:05PM
Mar 5, 2025 04:17PM
Mar 5, 2025 04:15PM Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
Feb 27, 2025 04:06PM
Feb 27, 2025 04:05PM
Feb 11, 2025 04:11PM
Feb 11, 2025 04:10PM
Feb 10, 2025 08:00AM
Feb 6, 2025 07:01AM
Feb 6, 2025 07:00AM Mustang Bio Announces Pricing of $8 Million Public Offering
Jan 14, 2025 08:02AM
Jan 14, 2025 08:00AM
Nov 14, 2024 04:10PM
Nov 12, 2024 08:31AM
Nov 12, 2024 08:30AM
Nov 7, 2024 08:32AM
Nov 7, 2024 08:30AM Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
Oct 24, 2024 02:10PM
Oct 24, 2024 02:10PM
Aug 13, 2024 04:05PM
Jun 21, 2024 04:01PM
Jun 20, 2024 08:01AM
Jun 20, 2024 08:00AM
Jun 17, 2024 08:31AM Mustang Bio (MBIO) Reports Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Trial of MB-106
Jun 17, 2024 08:30AM
May 15, 2024 04:15PM
May 2, 2024 04:01PM
Apr 29, 2024 08:00PM
Mar 28, 2024 04:05PM
Mar 28, 2024 09:03AM
Mar 28, 2024 09:00AM Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Mar 11, 2024 04:05PM
Mar 7, 2024 07:31AM
Mar 7, 2024 07:30AM
Jan 11, 2024 08:30AM
Dec 11, 2023 08:31AM
Dec 11, 2023 08:30AM
Nov 14, 2023 04:10PM Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Nov 14, 2023 04:05PM
Nov 2, 2023 09:28AM
Oct 30, 2023 02:15PM
Oct 26, 2023 12:31PM
Oct 26, 2023 12:30PM
Oct 26, 2023 09:03AM
Oct 26, 2023 09:00AM Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recu
Sep 7, 2023 08:15AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All